We are live on !
Find out more
Foundry Partners Portfolio holdings
AUM
$1.89B
Turnover
15.38%
1-Year Est. Return
9.84%
This Fund
S&P 500
This Quarter Est. Return
-3.32%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.05%
10 Year Est. Return
+297.72%
AUM
$1.59B
AUM Growth
-$73.3M
(-4.4%)
Cap. Flow
+$12.5M
Cap. Flow % of AUM
Cap. Flow %
0.79%
Top 10 Holdings %
Top 10 Hldgs %
19.06%
Holding
339
New
37
Increased
202
Reduced
75
Closed
23
Avg Time Held
2.8
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$21.8M |
| 2 |
BorgWarner
BWA
|
+$18.9M |
| 3 |
Hartford Financial Services
HIG
|
+$18.6M |
| 4 |
Cigna
CI
|
+$15.3M |
| 5 |
Fox Class A
FOXA
|
+$11.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$25.5M |
| 2 |
Centene
CNC
|
+$18.6M |
| 3 |
Qualcomm
QCOM
|
+$13.2M |
| 4 |
Ally Financial
ALLY
|
+$11.4M |
| 5 |
Verizon
VZ
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.2% |
| 2 | Healthcare | 13.26% |
| 3 | Industrials | 12.11% |
| 4 | Energy | 9.68% |
| 5 | Technology | 9.09% |
Similar funds
PAME
Foundry Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Foundry Partners held 339 positions worth $1.59B, down 4.4% from $1.66B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Foundry Partners's Q3 2022 filing shows 37 new, 202 increased, 75 reduced and 23 closed positions. Its largest new stake was Gilead Sciences: 345,955 shares worth $21.3M. The largest sale was Pfizer, an estimated $25.5M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Industrials.
- Foundry Partners's largest Q3 2022 buy was Gilead Sciences: 345,955 shares worth $21.3M.
- Foundry Partners added most to Altria Group in Q3 2022, an estimated $5.64M increase.
- Foundry Partners's biggest Q3 2022 reduction was Verizon, cutting an estimated $10.8M.
- Foundry Partners fully exited Pfizer in Q3 2022, selling an estimated $25.5M.
- Foundry Partners's ten largest holdings make up 19% of its $1.59B portfolio in Q3 2022.
- Foundry Partners opened 37 new positions and closed 23 in Q3 2022.
- Foundry Partners's portfolio value fell 4.4% quarter-over-quarter to $1.59B.
Based on Foundry Partners's 13F filing for Q3 2022, filed 21 Oct 2022.